Joseph E. Burgents

5.5k total citations · 3 hit papers
54 papers, 3.2k citations indexed

About

Joseph E. Burgents is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Joseph E. Burgents has authored 54 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Joseph E. Burgents's work include Prostate Cancer Treatment and Research (24 papers), Renal cell carcinoma treatment (19 papers) and PARP inhibition in cancer therapy (16 papers). Joseph E. Burgents is often cited by papers focused on Prostate Cancer Treatment and Research (24 papers), Renal cell carcinoma treatment (19 papers) and PARP inhibition in cancer therapy (16 papers). Joseph E. Burgents collaborates with scholars based in United States, United Kingdom and Canada. Joseph E. Burgents's co-authors include Fred Saad, Neal D. Shore, Karim Fizazi, Johann S. de Bono, Jinyu Kang, Shahneen Sandhu, Carrie A. Adelman, Joaquı́n Mateo, Antoine Thiery-Vuillemin and Oliver Sartor and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joseph E. Burgents

52 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020 1.4k citations Johann S. de Bono, Joaquı́n Mateo et al. New England Journal of Medicine profile →
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

2020 474 citations Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine profile →
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

2018 281 citations Noel W. Clarke, Paweł Wiechno et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Joseph E. Burgents

Since Specialization

Citations

This map shows the geographic impact of Joseph E. Burgents's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph E. Burgents with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph E. Burgents more than expected).

Fields of papers citing papers by Joseph E. Burgents

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph E. Burgents. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph E. Burgents. The network helps show where Joseph E. Burgents may publish in the future.

Co-authorship network of co-authors of Joseph E. Burgents

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph E. Burgents. A scholar is included among the top collaborators of Joseph E. Burgents based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph E. Burgents. Joseph E. Burgents is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 2025 ·European Urology ·Martin H. Voss, Howard Gurney, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae‐Lyun Lee, (unknown), V.P. Stus, Thomas Ferguson, Paweł Wiechno, Erhan Gökmen, Louis Lacombe, Craig Gedye, (unknown), (unknown), Joseph E. Burgents, Laurence Albigès	0
2	Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall Survival 2025 ·Targeted Oncology ·Manuela Schmidinger, Pratik Rane, (unknown), Eric Druyts, Joseph E. Burgents, Murali Sundaram, Avivit Peer	1
3	Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. 2024 ·Journal of Clinical Oncology ·Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas E. Hutson, Sun Young Rha, Jaime R. Merchan, Eric Winquist, Howard Gurney, Viktor Grünwald, Saby George, (unknown), Joseph E. Burgents, Răzvan Cristescu, Y. Narita, Cixin He, Zi-Ming Zhao, Chinyere E. Okpara, Yukinori Minoshima, Toni K. Choueiri	7
4	Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma 2024 ·Annals of Oncology ·Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas E. Hutson, Sun Young Rha, (unknown), Eric Winquist, Howard Gurney, Viktor Grünwald, S. George, (unknown), Joseph E. Burgents, Răzvan Cristescu, Perminder S. Sachdev, Y. Narita, Jie Huang, Zi-Ming Zhao, Chinyere E. Okpara, Yukinori Minoshima, Toni K. Choueiri	6
5	Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study 2024 ·European Urology ·Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Sun Young Rha, Javier Puente, Aly‐Khan A. Lalani, Eric Winquist, Masatoshi Eto, Naveen S. Basappa, Nizar M. Tannir, Ulka N. Vaishampayan, Georg A. Bjarnason, Stéphane Oudard, Viktor Grünwald, Joseph E. Burgents, Ran Xie, Jodi A. McKenzie, Thomas Powles	4
6	Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review 2023 ·European Urology ·Robert J. Motzer, Pratik Rane, (unknown), (unknown), Allison Martin Nguyen, Murali Sundaram, Joseph E. Burgents, (unknown), K. Rüdell	8
7	Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial 2022 ·The Lancet Oncology ·Fred Saad, Antoine Thiery-Vuillemin, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Arnold Degboe, Noel W. Clarke	21
8	KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer 2021 ·Future Oncology ·Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R Chandana, (unknown), Joseph E. Burgents, Karim Fizazi	32
9	Olaparib for Metastatic Castration-Resistant Prostate Cancer breakdown → 2020 ·New England Journal of Medicine ·Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain	1397
10	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer breakdown → 2020 ·New England Journal of Medicine ·Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Claire Corcoran, Carrie A. Adelman, Johann S. de Bono	474
11	610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations 2020 ·Annals of Oncology ·Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, K.N. Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, P. Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Claire Corcoran, Carrie A. Adelman, Maha Hussain	7
12	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial breakdown → 2018 ·The Lancet Oncology ·Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Carsten Goessl, Joseph E. Burgents, Robert Kozarski, Darren Hodgson, Maria Learoyd, Fred Saad	281
13	Migratory properties of pulmonary dendritic cells are developmentally programmed (61.4) 2012 ·The Journal of Immunology ·Donald N. Cook, Joseph E. Burgents, Hideki Nakano	3
14	The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells 2010 ·Cancer Research ·Hendrik W. van Deventer, Joseph E. Burgents, Qing Wu, Rita-Marie T. Woodford, W. June Brickey, Irving C. Allen, Erin McElvania, Jonathan S. Serody, Jenny P.‐Y. Ting	135
15	The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice 2010 ·Journal of Immunotherapy ·Joseph E. Burgents, Timothy P. Moran, Michelle L. West, Nancy Davis, Robert E. Johnston, Jonathan S. Serody	12
16	L-Selectin Is Dispensable for T Regulatory Cell Function Postallogeneic Bone Marrow Transplantation 2010 ·American Journal of Transplantation ·Michael Carlson, Lynette Fulton, James M. Coghill, Michelle L. West, Joseph E. Burgents, Yisong Y. Wan, Angela Panoskaltsis‐Mortari, Thomas F. Tedder, Bruce R. Blazar, Jonathan S. Serody	7
17	Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice 2007 ·Vaccine ·Timothy P. Moran, Joseph E. Burgents, Brian Long, Ivana R. Ferrer, Elizabeth M. Jaffee, Roland Tisch, Robert E. Johnston, Jonathan S. Serody	35
18	Expression Profiles of Na⁺,K⁺-ATPase during Acute and Chronic Hypo-osmotic Stress in the Blue CrabCallinectes sapidus 2006 ·Biological Bulletin ·Donald L. Lovett, Michael P. Verzi, Joseph E. Burgents, (unknown), Krzysztof Glomski, (unknown), David W. Towle	45
19	Effects of Hypoxia and Hypercapnic Hypoxia on the Localization and the Elimination ofVibrio campbelliiinLitopenaeus vannamei, the Pacific White Shrimp 2005 ·Biological Bulletin ·Joseph E. Burgents, Karen G. Burnett, Louis E. Burnett	52
20	Localization and bacteriostasis of introduced into the Pacific white shrimp, 2005 ·Developmental & Comparative Immunology ·Joseph E. Burgents, Louis E. Burnett, Eric V. Stabb, Karen G. Burnett	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact